J&J Can't Ax Pfizer Antitrust Suit Over Remicade Biosimilar
Pfizer Inc. has credibly shown that Johnson & Johnson may have flouted antitrust laws by coercing health insurers into not covering biosimilar versions of biologic Remicade, a Pennsylvania federal judge said...To view the full article, register now.
Already a subscriber? Click here to view full article